Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · IEX Real-Time Price · USD
53.75
+0.45 (0.84%)
May 16, 2024, 4:00 PM EDT - Market closed
Apogee Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Apogee Therapeutics stock have an average target of 65.8, with a low estimate of 40 and a high estimate of 91. The average target predicts an increase of 22.42% from the current stock price of 53.75.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for APGE stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +48.84% | May 10, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $37 → $75 | Strong Buy | Maintains | $37 → $75 | +39.53% | Mar 6, 2024 |
| Stifel | Stifel | Strong Buy Maintains $46 → $95 | Strong Buy | Maintains | $46 → $95 | +76.74% | Mar 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $44 → $91 | Strong Buy | Maintains | $44 → $91 | +69.30% | Mar 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $29 → $44 | Strong Buy | Maintains | $29 → $44 | -18.14% | Jan 3, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.59
from -3.36
EPS Next Year
-3.06
from -2.59
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 6.3M | 581.7M |
| Avg | n/a | n/a | n/a | 1.5M | 141.3M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 37,919.6% |
| Avg | - | - | - | - | 9,133.3% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -1.66 | -1.74 | -2.35 | -3.06 |
| Avg | -2.59 | -3.06 | -3.56 | -2.97 |
| Low | -3.19 | -4.03 | -4.72 | -2.85 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.